Gene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.47 alerts
Get alerted when Policy MP 5.01.47 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for beremagene geperpavec-svdt (Vyjuvek) and prademagene zamikeracel (Zevaskyn) for treatment of wounds in individuals with recessive dystrophic epidermolysis bullosa (RDEB). Affects providers prescribing or administering these therapies and members receiving them.
Relevant information and policy statements for prademagene zamikeracel (Zevaskyn) were added following FDA approval in April 2025; Zevaskyn may be considered medically necessary for RDEB when specified criteria and limits are met.
Additional criteria for Vyjuvek (beremagene geperpavec-svdt) were added.
Policy updated with literature review through June 1, 2025, and references on new therapies and trials were added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.